Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Biotechnology

Healthcare
$5.30 -2.45%

-$0.27 today

Market cap
$430.84M
Beta
0.51
P/E (TTM)
-5.6
EPS (TTM)
-$1.92
52W Low $7.61High $18.31

Volume 1.67M

Average 1.21M

PHAT Long-term Debt

Borrowings due after more than one year.

Phathom Pharmaceuticals, Inc.NASDAQ: PHAT

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt falls 70.1% from a year ago

Long-term debt stood at $163.68M at the end of Q1 FY2026, down 70.1% from a year earlier and down 21.7% from the prior quarter. Over 3 fiscal years it compounded at +30.0% a year.

Context

  • Long-term debt amounted to 53.6% of total assets at the end of Q1 FY2026, down 132.3 pp from a year earlier.
  • Long-term debt increased in 2 of the last 3 fiscal years.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -70.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$163.68M-21.7% QoQ
Last fiscal yearDec 2025
$209.09M-60.9% YoY
Year agoMar 2025
$547.05M-70.1% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-70.1%——
1 year-60.9%——
3-year CAGR+30.0%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
209.09M USD
Year-over-year change
-60.9%
4-year CAGR
+23.6%

Long-term Debt vs competitors

How PHAT compares with its peers on the latest reported figures

  • PHAT's Mar 2026 long-term debt of $163.68M is the lowest of the 2 companies compared; the peer median is $203.52M.
  • Its year-over-year change of -70.1% is the lowest of 2, against a peer median of +34.5%.
  • Long-term debt amounts to 53.6% of total assets for PHAT, versus a peer median of 40.3%.
PHAT Competitors Peer median
Long-term Debt for PHAT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ARDXArdelyx, Inc.Mar 2026$203.52M +34.5%—40.3%
PHATPhathom Pharmaceuticals, Inc.Mar 2026$163.68M -70.1%+30.0%53.6%
Peer median (excluding PHAT) $203.52M+34.5%—40.3%

Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents183.26M155.39M381.39M297.26M129.97M
Short-term Investments00000
Net Receivables001.64M38.8M78.13M
Inventory001.21M3.21M5.52M
Other Current Assets3.27M5.13M13.19M20.87M15.35M
Total Current Assets186.53M160.51M397.43M360.13M228.97M
Property, Plant & Equipment (Net)2.56M3.49M3.62M2.09M3.67M
Goodwill00000
Intangible Assets00000
Long-term Investments0505K02.86M0
Tax Assets00000
Other Non-current Assets341K299K12.79M13.23M26.51M
Total Non-current Assets2.91M4.3M16.41M18.18M30.18M
Total Assets189.43M164.81M413.84M378.32M259.15M
Account Payables5.15M10M12.6M10.51M4.98M
Short-term Debt00019.78M648K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities6.34M8.45M20.43M54.94M126.41M
Total Current Liabilities18.92M26.24M38.78M85.73M132.04M
Long-term Debt89.67M95.26M137.84M534.67M209.09M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7.5M117.03M309.52M11.5M354.12M
Total Non-current Liabilities98.35M213.39M447.82M546.17M565.27M
Total Liabilities117.28M239.62M486.6M631.9M697.32M
Common Stock3K3K5K6K6K
Retained Earnings(529.37M)(727.09M)(928.69M)(1.26B)(1.48B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity72.16M(74.81M)(72.76M)(253.58M)(438.17M)
Total Debt91.34M97.07M139.03M554.95M211.8M
Net Debt(91.92M)(58.32M)(242.36M)257.68M81.83M

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Intrinsic Alpha fair value

Locked

Current Price

$5.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.